Oct 30 (Reuters) - Theratechnologies Inc TH.TO :
* TROGARZO® PHASE III DATA ANALYSIS PRESENTED AT HIV DRUG THERAPY GLASGOW 2018: PATIENTS NOT ACHIEVING PRIMARY ENDPOINT AT DAY 7 EXPERIENCED CLINICAL BENEFIT BY END OF STUDY
* THERATECHNOLOGIES INC - OF 40 PATIENTS ENROLLED IN PHASE III CLINICAL TRIAL, ONLY SEVEN DID NOT ACHIEVE PRIMARY ENDPOINT.
* THERATECHNOLOGIES INC - PATIENTS IN THE STUDY WHO DID NOT ACHIEVE PRIMARY ENDPOINT EVENTUALLY DID EXPERIENCE CLINICAL BENEFITS DURING STUDY.